FilingReader Intelligence
Sino Biopharmaceutical secures US FDA approval for LM-350
July 24, 2025 at 05:00 PM UTC•By FilingReader AI
Sino Biopharmaceutical's subsidiary LaNova Medicines received US FDA Investigational New Drug approval for LM-350, an antibody-drug conjugate targeting CDH17 in gastrointestinal tumors.
The company now has five ADC products in clinical stages, with nearly ten more in preclinical development.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1177•Hong Kong Exchange
News Alerts
Get instant email alerts when Sino Biopharmaceutical publishes news
Free account required • Unsubscribe anytime